Tisch Multiple Sclerosis Research Center of New York Study Featured in BioSpace streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MSC-NPs are seen as a possible way of treating people with progressive MS, who have few effective disease-modifying treatments available. They are essentially stem cells collected from a patient’s bone marrow that are expanded and matured to produce factors involved in modulating the immune response and in nervous tissue growth and survival.
An open-label Phase 1 trial (NCT01933802) investigated this stem cell treatment in 20 adults with stable primary (four PPMS patients) or secondary progressive MS (16 SPMS patients) and significant disability.
All received a total of three injections of MSC-NPs, given directly into the spinal canal three months apart. They were then evaluated at three and six months, and again at two years, after the final treatment to determine its long-term safety and tolerability, and for signs of potential effectiveness.